Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice
-
Published:2024-07
Issue:7
Volume:8
Page:688-698
-
ISSN:2468-6530
-
Container-title:Ophthalmology Retina
-
language:en
-
Short-container-title:Ophthalmology Retina
Author:
Melillo PaoloORCID,
Testa Francesco,
Di Iorio Valentina,
Karali MarianthiORCID,
Citro Amelia,
Della Corte Michele,
Rossi Settimio,
Banfi SandroORCID,
Simonelli FrancescaORCID
Reference43 articles.
1. Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials;Maguire;Ophthalmology,2019
2. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial;Russell;Lancet,2017
3. Macular fold complicating a subretinal injection of voretigene neparvovec;Ducloyer;Ophthalmol Retina,2020
4. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec;Kortüm;Acta Ophthalmol,2022
5. Visual acuity, retinal morphology, and patients’ perceptions after voretigene neparovec-rzyl therapy for RPE65-associated retinal disease;Sengillo;Ophthalmol Retina,2022